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Tumor suppressorThe expression of miR-203 has been reported to be signiﬁcantly down-regulated in esophageal cancer.
We showed here that overexpression of miR-203 in esophageal cancer cells dramatically increased cell
apoptosis and inhibited cell proliferation, migration and invasion as well as tumor growth and down-reg-
ulated miR-21 expression. We subsequently identiﬁed that small GTPase Ran was a target gene of miR-
203. Furthermore, Ran restoration partially counteracted the tumor suppressive effects of miR-203 and
increased miR-21 expression. Taken together, our ﬁndings suggest that miR-203 may act as novel tumor
suppressor in esophageal cancer through down-regulating the expression of Ran and miR-21.
 2013 Elsevier Ireland Ltd. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Esophageal cancer is sixth leading cause of cancer death world-
wide with a variable geographic distribution. Twomain histological
types have been identiﬁed, esophageal squamous cell carcinoma
(ESCC) andesophageal adenocarcinoma (EAC), regarding todifferent
etiologic and pathologic characteristics. EAC is common in western
countries while ESCC is frequent in east Asia, especially in China
whose incidence in thehigh-risk northern and central China exceeds
100 cases per 100,000 people per year [1]. Despite improvements in
the diagnosis and treatment of this cancer, the overall survival for
advanced and metastatic esophageal cancer is still poor, with a 5-
year survival rate of less than 20% after surgery in China [1].
Thus, there is a great need to disclose molecular mechanisms of
pathogenesis of esophageal cancer to identify more tumor speciﬁc
biomarkers and therapeutic targets for early diagnosis and treat-
ment. The pathogenesis of esophageal cancer still remains unclear
so far. It has been shown that both genetic and epigenetic altera-tions may be involved in the progress of this cancer. Genetic abnor-
malities such as gene ampliﬁcation and mutation, chromosomal
loss and gain or loss of heterozygosity (LOH) are important etiolog-
ical factor involved in tumorigenesis of esophageal cancer [2]. Re-
cently, epigenetic disruption such as aberrant CpG island
methylation has been demonstrated as a key event in the develop-
ment of esophageal cancer via regulating the expression of tumor-
related genes and microRNAs (miRNAs) [3].
MiRNAs are an endogenous class of 20–25 nucleotide-long sin-
gle-stranded non-coding RNAs that regulate gene expression at the
posttranscriptional level by binding to the 30-untranslated region
(30-UTR) of mRNA which subsequently leads to mRNA degradation
and translation repression. Previous studies have demonstrated
that a single miRNA may target multiple genes due to the imper-
fect complementarity with target mRNA, while the expression of
a single gene may be modulated by different miRNAs [4]. The
remarkable performance of individual miRNAs to modulate multi-
ple transcripts allows miRNAs to control a variety of physiological
processes such as cell proliferation, differentiation and apoptosis.
Thus, alterations in miRNA expression are thought to play critical
roles in cancer initiation and progression through regulating the
expression of various oncogenes and tumor suppressive genes [5].
Over the past few years, aberrant miRNA expression proﬁles
were reported in esophageal cancer tissues compared with
matched non-malignant tissues [3,6]. MiR-21 was observed to be
frequently up-regulated in ESCC cell lines and tumor tissues [7].
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373, miR-192, miR-196a and miR-147, was also detected in ESCC
[8–13]. Among them, the overexpression of miR-129 has been ob-
served to be associated with poorer post-operative survival [14].
Several other miRNAs were reported to be down-regulated in ESCC
such as miR-203, miR-375, miR-125b, miR-100, miR-133a, miR-
133b, miR-143 and miR-145 [12,15–17], suggesting they may exert
tumor suppressive functions. It has been reported that miR-133a,
miR-133b and miR-145 suppressed tumor cell growth and invasion
through targeting FSCN1 gene [15].
MiR-203 locates at chromosome 14q32-33 and has been identi-
ﬁed as a skin-speciﬁc keratinocyte-derived miRNA involved in
keratinocyte differentiation [18]. Previous report showed that
overexpression of miR-203 inhibited the proliferation of esopha-
geal cancer cells through targeting DNp63 [19]. However, further
studies are needed to provide novel insights into molecular mech-
anisms underlying the regulatory activities of miR-203 in esopha-
geal cancer. In our present studies, regulatory functions of miR-203
on the proliferation, apoptosis, migration and invasion of esopha-
geal cancer cells as well as on tumor growth in vivo and its molec-
ular mechanisms were characterized.
2. Materials and methods
2.1. Plasmid constructs
Hsa-miR-203 (miR-203) precursor was purchased from Songon Tech (Beijing,
China) and inserted into pcDNA6.2-GW/EmGFP-miR vector (named pcDNA/miR-
203) according to the manufacturer’s instructions (Invitrogen, USA). Scramble miR-
NA was cloned into the same vector and used as negative control (named pcDNA/
miR-NC). The sequence of control miRNA is 50-AGGTACGAAACGCTAAGAAT-30 . To
construct luciferase reporter vector, the human small GTPase Ran 30-UTR containing
putative binding sites for miR-203 was ampliﬁed by PCR and cloned in pmirGLO
Dual-Luciferase miRNA Target Expression Vector (Promega, USA) into restriction
sites Sac-1 and Sal-1. The construct was named pmiR-GLO-Ran. The primers used
were as follows: 50-CTAAGCGGAACATGTGCTTCATCT-30 (Forward primer for Ran
30UTR), 50-GATATTTGAAATACAACTTTATTC-30 (Reverse primer for Ran 30UTR). As a
control, pmiR-GLO-Ran-Mut vector was constructed by site-directed mutagenesis
using pmiR-GLO-Ran plasmid as template. For the mutated construct, three nucle-
otides TCA in miR-203 seed match site were substituted with CGC. The primers
used were as follow: 50-TATAGGCAGCTGTCCTGTGATGTC-30 (Forward primer for
Ran 30UTR-Mut), 50-GGCGAATACAACTTTATTCTGATT-30 (Reverse primer for Ran
30-UTR-Mut). The accuracy of all cloning was conﬁrmed by sequencing.2.2. Cell transfection
Human esophageal squamous cancer cell line (Ec-109) was kindly provided by
Dr. Ling Zhou from Institute for Viral Disease Control and Prevention, Chinese Cen-
ter for Disease Control and Prevention (CDC). Cells were cultured and maintained in
RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin
and 100 lg/ml streptomycin in a humidiﬁed incubator with 5% CO2 at 37 C. All cul-
ture materials were purchased from GIBCO, USA. Cell transfection was performed
using Lipofectamine 2000 (Invitrogen, USA). Brieﬂy, cells at approximately 60% con-
ﬂuence in 6-well plates were transfected with miR-203 expressing vector (pcDNA/
miR-203) or control vector (pcDNA/miR-NC). Stable miR-203 overexpressing clones
and control transfected-cells were selected by using blasticidin at a concentration
of 4 lg/ml. Individual clones were isolated after 3 weeks of selection and the
expression of miR-203 was conﬁrmed by real-time PCR.
Small GTPase Ran-directed small interfering RNA (siRNA) oligonucleotide was
purchased from Inovogen Tech (Beijing, China). The sequence is:siRNA-425-Ran:
50-GCAACAAAGUGGAUAUUAA-30 .
Scramble siRNA was used as negative control (siRNA-NC). The sequence is 50-
UUCUCCGAACGUGUCACGUTT-30 . SiRNA oligonucleotide duplexes were synthesized
and 1 lg of siRNA mimic was transfected into cells by using Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer’s guidelines.2.3. Clinical samples
Twelve pairs of primary esophageal squamous cell carcinoma tissues and corre-
sponding adjacent normal esophageal tissues were obtained from patients in Jiey-
ang City People’s Hospital with informed consent and agreement. All tissue
samples were collected from untreated patients undergoing surgery and were
immediately frozen in liquid nitrogen and stored at 80 C until for the extraction
of total RNA.2.4. Quantitative real-time PCR (qRT-PCR)
Real-time PCR was used to detect the expression of mature miR-203, miR-21
and the expression of primary transcript of small GTPase Ran. Total RNA was ex-
tracted from cultured cells or frozen tissues using Trizol reagent (Invitrogen, USA)
following the protocols of the manufacturer. For miRNA expression analysis, 1 lg
of total RNA was applied for reverse transcription to synthesize miRNA cDNA using
NCode™ VILO™miRNA cDNA synthesis kit (Invitrogen, USA). QRT-PCR analysis was
performed using EXPRESS SYBR GreenER™ miRNA qRT-PCR kit (Invitrogen, USA)
based on manufacturer’s instructions. 20 ll of the reverse transcription mix was
ampliﬁed by PCR with denaturation at 95 C for 2 min and 40 cycles at 95 C for
10 s and 60 C for 1 min. U6 was used as an endogenous control for normalization.
Each sample was analyzed in triplicate.
Primer sequences used were as follows: 50-GCGTGAAATGTTTAGGACCACTAG-30
(RT primer for miR-203), 50-CGGTAGCTTATCAGACTGATGTTGA-30 (RT primer for
miR-21), 50-GCTTCGGCAGCACATATACTAAAAT-30 (RT primer for U6).
For gene expression analysis, 1 lg of total RNA was reverse transcribed in a ﬁnal
volume of 20 ll to synthesize ﬁrst-strand cDNA using ImProm-II™ reverse tran-
scription system (Promegra, USA) according to the instructions of the manufacturer.
The transcript levels were detected by real-time PCR using Brilliant II SYBR green
qPCR master mix (Stratagene, USA) to monitor ampliﬁcation. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an endogenous control to normal-
ize expression. 25 ll PCR reactions in triplicate were carried out by an initial dena-
turation at 95 C for 10 min followed by 40 cycles, each consisting of 30 s at 95 C,
30 s at 58 C, 30 s at 72 C and then 1 cycle for melting curve consists 1 min at 95 C,
30 s at 55 C, 30 s at 95 C. Primer sequences used were as follows: 50-
TGGCTTGCTAGGAAGCTCAT-30 (Forward primer for Ran), 50-CACCGCTGACATCA-
CAGGAC-30 (Reverse primer for Ran), 50-AGAAGGCTGGGGCTCATTTG-30 (Forward
primer for GAPDH), 50-AGGGGCCATCCACAGTCTTC-30 (Reverse primer for GAPDH).
The 244Ct method for relative quantiﬁcation of gene expression was used to deter-
mine miRNAs and Ran mRNA expression levels. Real-time PCR primers were de-
signed using Primer Express software (version 5.0, Applied Biosystems).2.5. Cell proliferation, cell cycle and apoptosis analysis
5.0  104 cells were inoculated in 25 cm2 ﬂasks with 5 ml fresh media in tripli-
cate. Viable cells were counted by trypan blue exclusion method with a hemacy-
tometer every 24 h. Every sample was counted three times, and an average cell
density was calculated. For cell cycle analysis, cultured cells were harvested,
washed twice by PBS, and ﬁxed in 70% ethanol at 4 C overnight. Cells were incu-
bated with propidium iodide at room temperature for 1 h and were analyzed by
ﬂow cytometry (Beckman, USA). For apoptosis analysis, miR-203 and control-trans-
fected cells were processed by using PE annexin V apoptosis detection kit (BD, USA)
in compliance with the manufacturer’s protocol and subjected to ﬂow cytometric
analysis (Beckman, USA).2.6. Transwell migration and invasion assays
The migration and invasion assays were carried out using Transwell insert
chambers (Corning, USA). For migration assay, 1  105 cells were plated into the
upper chamber in serum-free medium in triplicate. Medium containing 20% FBS
in the lower chamber served as chemoattractant. After incubation for 24 h at
37 C in a 5% CO2 humidiﬁed incubator, cells in the upper chambers were removed
by wiping with a cotton swab and cells migrated to the lower surface of ﬁlter were
ﬁxed in 70% ethanol for 30 min and stained with 0.2% crystal violet for 10 min. Cell
migration was scored by counting ﬁve random ﬁelds per ﬁlter under a light micro-
scope. For invasion assay, 3  105 cells were seeded into upper chambers precoated
with matrigel (BD, USA) in serum-free medium in triplicate. Medium with 20% FBS
were added to the lower chamber to serve as chemoattractant. After incubation for
24 h at 37 C, non-invading cells on the upper surface of ﬁlter were removed with
cotton swabs and invading cells that migrated to the lower surface of ﬁlter were
ﬁxed, stained and scored as described above.2.7. Lentivirus production and transduction
Lentiviral particles expressing wild-type human small GTPase Ran were pro-
duced with ViraPower Lentiviral Packaging Kit (Invitrogen, USA). The coding region
of human small GTPase Ran was ampliﬁed by PCR and subcloned into EcoRI and
XhoI sites of pLenti6.4/CMV/V5-MSGW/lacZ lentiviral vector (Invitrogen, USA) to
generate pLCM-Ran construct. The primers used are 50-CGGAATTCGCCACCATGGCT
GCGCAGGGAG-30 (Forward primer) and 50-CCCTCGAGTCACAGGTCATCATCCTCAT-30
(Reverse primer). The EmGFP-expressing lentiviral vector derived from pLenti6.2-
GW/EmGFP by Gateway reactions severed as negative control (pLCM). 293FT cells
at 70% conﬂuence in 10-cm tissue culture dishes were simultaneously transfected
with 3 lg of recombinant plasmids and 9 lg ViraPower Packaging Mix (Invitrogen,
USA) according to manufacturer’s instructions. The culture medium was changed
24 h posttransfection and the cells were cultured for an additional 48 h. The media
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Viral particles were stored at 80 C after ﬁltration with 0.45 lm ﬁlters (Millipore,
USA). The titers of lentiviral stocks were determined by ﬂow cytometry.
Wild-type human small GTPase Ran was eventually transduced into miR-203
transfected-Ec-109 cells by lentiviral infection (named miR-203 + pLCM-Ran). Len-
tiviral vector was introduced into miR-203 transfected-Ec-109 (named miR-
203 + pLCM) and miR-NC cells (named miR-NC + pLCM) which were used as nega-
tive controls. The expression of wild-type human Ran in miR-203 transfected-Ec-
109 cells was visualized by Western-blot. Transduction efﬁciency was optimized
and assessed by ﬂow cytometry for GFP-positive cells.
2.8. Soft-agar colony assay
Anchorage-independent cell growth was assayed in 6-well plates. 1  104 cells
were seeded in 2 ml of standard growth medium containing 0.3% low-melting-tem-
perature soft-agar (Lonza, USA) and plated onto solidiﬁed 0.7% soft-agar base layer
dissolved in complete culturemedium in6-well plates. Cultureswere fed onceaweek
with 0.5 ml of completemedium. Triplicate sampleswere prepared for each transfec-
tant and the experiment was repeated twice. Colonies becoming visible microscopi-
cally after 4 weekswere photographedwith anOlympus phase-contrastmicroscope.
2.9. In vivo tumorigenesis assay
Female athymic BALB/C nude mice (4–6 weeks) were purchased from Labora-
tory Animal Center of the Army Research Center (Beijing, China). All animals were
housed at pathogen-free condition. Animal experiments were performed in accor-
dance with current guidelines for the Care and Use of Laboratory Animals of Army
Research Center. All experimental procedures were conducted with the guidelines
provided by NIH (National Cancer Institute, USA. Website: http://ncifrederick.can-
cer.gov/Lasp/Acuc/Frederick/GuidelinesFnl.aspx). For xenografts, nude mice were
divided into 4 groups (n = 8 for each) and were subcutaneously (s.c.) inoculated into
the right ﬂanks with 2 x 106 or 1  107 of miR-203-transfected or scramble control-
transfected cells, respectively. Mice (n = 8) injected with 2  106 of Ec-109 cells
were used as positive control. For inoculation of Ran-restored cells, mice (n = 8
for each) were injected s.c. with 2  106 of Ec-109, miR-203 + pLCM-Ran, miR-
203 + pLCM and miR-NC + pLCM cells, respectively. Tumor sizes were measured
every 5 days using caliper. Tumor volumes (cm3) were calculated by using the fol-
lowing standard formula: [length width]  [(length + width)/2]. Mice were sacri-
ﬁced and photographied at 5 weeks postinjection.
2.10. Western blotting analysis
Cultured cells were harvested and lysed with RIPA lysis buffer (Beyotime, Chi-
na) for 10 min on ice. After centrifugation at 12,000g for 10 min, the concentration
of proteins was measured using Bradford’s reagent (Bio-Rad laboratories, USA). The
protein samples were denatured by boiling for 10 min and loaded onto SDS–PAGE
(12%) gel for electrophoresis. The proteins were transferred onto PVDF membrane
(Millipore, USA) which was then incubated in the blocking solution (5% non-fat
dried milk) at room temperature for 1 h. The anti-Ran antibody (Novus, USA) was
added into blocking solution and incubated at 4 C overnight. The membranes were
subsequently incubated with the secondary goat anti-mouse antibody conjugated
with ﬂuorescent dyes: IRDye 800 CW (KPL, USA) for 45 min. Protein expression
was normalized against GAPDH expression (RD, USA). Blotting images were ac-
quired with the Odyssey infrared imaging system (Li-COR Biosciences, USA) and
analyzed by the software provided by the manufacturer.
2.11. Dual-luciferase reporter assay
For luciferase reporter assay, Ec-109 cells (2.5  105) seeded in 6-well plates
were cotransfected with 0.5 lg of miR-203 expressing plasmid and 0.5 lg of
pmiR-GLO-Ran or pmir-GLO-Ran-Mut plasmids using Lipofectamine 2000. Empty
vector was used as negative control (pmiR-GLO-NC). At 24 h post-transfection,
luciferase activity was analyzed using the Dual-Glo Luciferase Assay System (Pro-
mega, USA). Luciferase activity was presented as an average of three independent
experiments performed in triplicate.
2.12. Statistical analysis
Data are expressed as mean ± SD from at least three separate experiments. The
differences between groups were analyzed using Student’s t-test. The difference
was deemed statistically signiﬁcant at p < 0.05.
3. Results
3.1. Overexpression of miR-203 induces cell apoptosis, suppresses cell
proliferation, migration and invasion and inhibits tumorigenicity
The expression of miR-203 has been reported to be signiﬁcantly
down-regulated in ESCC [3]. However, the involvement of miR-203in the pathogenesis of esophageal cancer is still far from being fully
elucidated. In current studies, to investigate the potential impacts
of miR-203 on the proliferation, apoptosis, migration, invasion and
tumorigenicity of esophageal cancer cells, miR-203 precursor and
scramble miRNA was cloned and exogenously expressed in esoph-
ageal cancer cells. Stably transfected cells were selected by blastic-
idin. The ectopic expression of mature miR-203 in stable
transfectants was conﬁrmed by qRT-PCR (Supplementary Fig. 1).
In order to investigate the impact of miR-203 on cell prolifera-
tion and cell cycle progress, trypan blue exclusion assay was car-
ried out to measure cell growth and cell cycle analysis was
conducted with ﬂow cytometry. The data showed that overexpres-
sion of miR-203 suppressed the proliferation of Ec-109 cells (Sup-
plementary Fig. 2A), modulated cell cycle by inducing G1 arrest
and decreased the percentages of Ec-109 cells in S phase compared
to control (Supplementary Fig. 2B). Our observations are consistent
with previous report [19]. Resistance to apoptosis is a critical hall-
mark of tumor cells for limitless proliferation. Flow-cytometric
analysis showed that the proportion of early apoptotic cells was
signiﬁcantly increased in miR-203-transfected Ec-109 cells com-
pare with control cells. The early apoptosis rate reached 25.8% in
miR-203-transfected cells compared to 15.4% in control cells, indi-
cating that ectopic expression of miR-203 could trigger apoptosis
enhancement in Ec-109 cells (Supplementary Fig. 3).
Transwellmigrationandmatrigel invasionassayswereperformed
to assess the effects of miR-203 on cell migration and invasion. As
shown in Fig. 1A and B, compared to the scramble control, exogenous
expression of miR-203 could effectively repress themigration ability
and invasion capacity of Ec-109 cells by about 32.4% (p < 0.01) and
about 76.8% (p < 0.01), respectively, indicating suppressive effects of
miR-203 on the migration and invasion of ESCCs.
We next examined the effects of miR-203 on the tumorigenicity
of esophageal cancer cells. Anchorage-independent growth assay
demonstrated that miR-203-transfected cells generated much few-
er and smaller colonies in soft agar compared with control trans-
fectants (Fig. 1C). For tumor formation assay in nude mice,
animals (n = 8) were initially inoculated s.c. with 2.0  106 of
miR-203 or scramble control-transfected cells, respectively. Ani-
mals (n = 8) injected s.c. with 2.0  106 of Ec-109 cells were used
as positive control. Tumor growth was evaluated for 35 days after
injection. Obvious tumor formation was detected in all of 8 nude
mice inoculated with 2.0  106 of Ec-109 cells or scramble con-
trol-transfected cells. In contrast, no signiﬁcant tumor formation
was observed in nude mice inoculated with 2.0  106 of miR-
203-transfected cells (Fig. 1D).
We thereafter decided to examine tumor formationby increasing
the numbers of injected cells. 1  107 of miR-203 or scramble con-
trol-transfected cells were subsequently inoculated in nude mice
(n = 8 for each). After 35 days, tumor growth was observed in 3 of
8 nudemice inoculated with miR-203-transfected cells. In contrast,
all 8 control mice developed tumors. However, evaluation of tumor
volumes and tumorweights at the sacriﬁce time eventually showed
that tumors induced bymiR-203-transfected cellsweremuch smal-
ler and lighter than those induced by control cells (Fig. 1E–G). Fur-
thermore, a higher expression of miR-203 was detected in tumors
induced by miR-203-transfected cells relative to the control (Sup-
plementary Fig. 4). Inhibitory effects of miR-203 on the migration
and invasion as well as tumorigenicity of esophageal cancer cells
suggest that miR-203 plays a tumor-suppressing role in ESCCs.
3.2. Small GTPase Ran is a direct target gene of miR-203
In order to disclose the molecular mechanism through which
miR-203 realizes its tumor-suppressive functions, computational
prediction using open access websites including TargetScan
(http://www.targetscan.org), PicTar (http://pictar.mdc-berlin.de)
Fig. 1. Overexpression of miR-203 represses cell migration and invasion and inhibits tumorigenicity. (A) Photomicrographs of transwell ﬁlters showing the cells which across
an 8-lm pore size membrane through migration without matrigel. 200magniﬁcation. Quantitative determination of cell migration performed in triplicate was presented as
means ± SD, p < 0.01. (B) Photomicrographs of transwell ﬁlters showing the cells which across an 8-lm pore size membrane with matrigel. 200magniﬁcation. Quantitative
determination of cell invasion performed in triplicate was presented as means ± SD, p < 0.01. (C) Colony formation assay was performed to test anchorage-independent
growth in soft agar of scramble miRNA and miR-203-transfected Ec-109 cells. 200 and 40magniﬁcation. Quantitative analysis of colony formation performed in triplicate
was presented as means ± SD, p < 0.05. (D) Xenograft model in nude mice. 2.0  106 of scramble miRNA and miR-203–transfected Ec-109 cells were injected s.c. into one
ﬂank of nude mice. No obvious tumor growth was observed in mice inoculated with miR-203-transfected Ec-109 cells compared to controls. (E) 1.0  107 of scramble miRNA
and miR-203-transfected Ec-109 cells were injected s.c. into one ﬂank of nude mice. Tumor volumes were measured at indicated time-points (n = 8 each group). The values
shown are the mean ± SD, p < 0.05. (F) Representative tumor tissues were extracted from mice inoculated with scramble miRNA and miR-203-transfected Ec-109 cells. (G)
Tumor weight was calculated and shown as means ± SD, p < 0.05.
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methods previously reported [20,21] were adopted to identify
functionally relevant targets of miR-203. Small GTPase Ran was
found to be the target gene of miR-203, which contains putative
target sequence. Compared to control, the decreased expression
of this protein in miR-203-transfected cells was conﬁrmed by both
Western-blot (Fig. 2A) and real-time PCR (Fig. 2B).We further tested whether Ran protein is a direct target of
miR-203 by luciferase assay. 30-UTR region of Ran-encoding gene
containing putative binding site of miR-203 and its site-directed
substitution mutant (Fig. 2C) were cloned into luciferase reporter
vector (named PmiR-GLO-Ran and PmiR-GLO-Ran-mut, respec-
tively) and co-transfected with miR-203, respectively. Cells
co-transfected with empty vector (PmiR-GLO-vector) and
Fig. 2. MiR-203 targets small GTPase Ran gene. (A) The expression of small GTPase Ran in scramble miRNA and miR-203-transfected Ec-109 cells was analyzed by Western
blot. GAPDH was used as an internal control. (B) The expression of Ran was quantitatively detected at transcriptional level by real-time PCR. Experiments were carried out in
triplicate and all data were shown as means ± SD, p < 0.01. (C) Putative miR-203-binding sequence within the 30-UTR of Ran mRNA. Mutations in the complementary site for
the seed region of miR-203 in 30-UTR of Ran gene were indicated. (D) The reporter plasmids containing wild type of 30-UTR of Ran gene (pmiR-GLO-Ran) or mutant (pmiR-
GLO-Ran-Mut) were co-transfected into Ec-109 cells with miR-203 expressing plasmid to evaluate luciferase activity. Empty plasmid without 30-UTR of Ran gene was used as
control (pmiR-GLO-NC). The normalized luciferase activity in control-transfectant was set as relative luciferase activity. Data were presented as means ± SD (n = 3), p < 0.05.
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tive luciferase activity was signiﬁcantly down-regulated by about
43.5% in the reporter construct containing wild type 30-UTR com-
pared to the mutant and empty vector control (Fig. 2D). These re-
sults suggest that small GTPase Ran is a direct downstream target
gene of miR-203 and miR-203 suppresses the expression of Ran
through directly binding to its 30-UTR.3.3. MiR-21 is down-regulated by miR-203 through targeting small
GTPase Ran
MiR-21 has been identiﬁed as the most commonly overexpres-
sed oncogenic miRNA in solid tumors including ESCC [22,23]. In or-
der to verify whether ectopic expression of miR-203 could
inﬂuence the expression of miR-21, we compared the expression
of miR-21 in miR-203- and vector control-transfected Ec-109 cells
by real-time PCR. The results showed that the expression of miR-21
was signiﬁcantly reduced in miR-203-transfected Ec-109 cells to
about 45.8% of the control (p < 0.01) (Fig. 3A), suggesting that
miR-203 could be a potential negative regulator for miR-
21expression.
Small GTPase Ran was identiﬁed as a direct target gene of miR-
203 in our current studies, we further examined whether miR-203
down-regulated miR-21 expression through repressing Ran. To
verify this hypothesis, we designed Ran speciﬁc siRNAs to speciﬁ-
cally suppress the expression of Ran in Ec-109 cells and the expres-
sion level of miR-21 in Ran speciﬁc siRNAs-transfected cells was
compared with that in scramble siRNA-transfected cells which
were used as negative control (siRNA-NC). After transfection of siR-
NAs into Ec-109 cells, compared to scramble control, signiﬁcant
suppression of Ran expression was found in Ran speciﬁcsiRNA-transfected cells (siRNA-425-Ran) by both Western-blot
(Fig. 3B) and real-time PCR (p < 0.01) (Fig. 3C) analyses.
Following this conﬁrmation, the expression level of miR-21 was
analyzed by real-time PCR in siRNA-425-Ran- and scramble control
siRNA-transfected cells. The results showed that the expressions of
miR-21 was remarkably down-regulated in Ran speciﬁc siRNA-
transfected Ec-109 cells compared to control-transfected cells
(p < 0.01) (Fig. 3D). These data suggest that the decreased expres-
sion of miR-21 correlates with the speciﬁc Ran silencing by siRNA
suppression and miR-203 may down-regulate miR-21 expression
through repressing Ran. However, the analysis also showed that
the expression of Ran and miR-21 was lower in tumors induced
by miR-203-transfected cells than in those induced by scramble
control miRNA-transfected cells (Supplementary Fig. 5). Data ob-
tained suggest that miR-203 may be one of the critical events that
modulate the expression of oncogenic protein small GTPase Ran
and oncomir miR-21 in esophageal cancer.
3.4. Restoration of Ran counteracts the tumor suppressive effects of
miR-203
We identiﬁed here that miR-203 exerted tumor suppressive
effects in ESCCs and small GTPase Ran was its direct target gene.
To investigate whether the regulatory effects of miR-203 on the
apoptosis, proliferation, migration, invasion and tumor formation
of Ec-109 cells aremediated by Ran, we cloned ORF of wild-type hu-
man Ran without its 30-UTR into lentiviral expression vector to
avoid miRNA interfering. Ran was exogenously expressed in miR-
203-transfected Ec-109 cells by lentivirus infection (named
miR-203 + pLCM-Ran). Empty lentiviral vector was introduced in
miR-203-transfected Ec-109 cells (named miR-203 + pLCM) and
miR-NC cells (namedmiR-NC + pLCM)which were used as negative
Fig. 3. MiR-203 down-regulates miR-21 expression through Ran. (A) Quantitative analysis of miR-21 expression in miR-203 and scramble miRNA-transfected Ec-109 cells by
real-time PCR. Experiments were performed in triplicate and expressed as means ± SD, (p < 0.01). (B) The expression of Ran in Ran speciﬁc siRNA (siRNA-425-Ran) -
transfected Ec-109 cells was compared with that in scramble siRNA-transfected Ec-109 cells (siRNA-NC). GAPDH was used as an internal control. (C) The expression of Ran
was quantitatively analyzed by real-time PCR. Analysis was performed in triplicate and all data were shown as means ± SD, p < 0.01). (D) Quantitative analysis of miR-21
expression in scramble siRNA (siRNA-NC) and Ran speciﬁc siRNA (siRNA-425-Ran)-transfected Ec-109 cells. Analysis was carried out in triplicate and all data were presented
as means ± SD, p < 0.01).
126 F. Zhang et al. / Cancer Letters 342 (2014) 121–129control. Ran restoration in miR-203-transfected Ec-109 cells was
subsequently conﬁrmed by Western-blot (Supplementary Fig. 6).
Our analysis further found that Ran restoration not only increased
the proliferation (Supplementary Fig. 7) and the apoptosis resis-
tance (Supplementary Fig. 8) of miR-203-trasnfected cells but also
partially increased their capacity ofmigration (Fig. 4A) and invasion
(Fig. 4B) when compared with negative control, indicating that the
suppressive effects of miR-203 on cell migration and invasion could
be partially rescued by Ran restoration.
We showed above that miR-21 expression could be down-reg-
ulated by miR-203, we thereafter examined the effect of Ran resto-
ration in miR-203-transfected cells on the expression of miR-21.
Our results showed that restoring expression of Ran increased
miR-21 expression by about 2 folds (p < 0.01) (Fig. 4C), indicating
that Ran restoration counteracts the inhibitory effects of miR-203
on miR-21 expression.
MiR-21 expression was up-regulated by Ran restoration, we
therefore investigated its implication in anti-tumor effects of
miR-203 using xenograft experiments. 2  106 miR-203 + pLCM-
Ran cells were inoculated in nude mice (n = 8). Ec-109 and miR-
NC + pLCM cells were used as positive controls (8 mice for each).
MiR-203 + pLCM cells were used as negative control (n = 8). Our
experiments showed that Ec-109 and miR-NC + pLCM cells in-
duced tumor formation in all nude mice and no obvious tumor for-
mation was observed in mice inoculated with MiR-203 + pLCM
cells. Interestingly, miR-203 + pLCM-Ran cells induced tumor for-
mation in 2 of 8 inoculated mice (Fig. 4D), indicating that restora-
tion of Ran in miR-203-transfected cells could partially rescue anti-
tumor effects of miR-203. However, evaluation of tumor volumes
and measurement of tumor weights at the sacriﬁce time demon-
strated that tumors induced by Ran restoration were much smallerand lighter than those induced by controls (Fig. 4E–G). Data ob-
tained suggest that miR-203 inhibits Ec-109 cell tumor formation
by suppressing Ran and Ran restoration partially counteracts
anti-tumor functions of miR-203.3.5. MiR-203 expression inversely correlates with the expression of
Ran and miR-21 in ESCC
The expression of miR-203, Ran and miR-21 was quantitatively
analyzed by real-time PCR in 12 pairs of primary ESCC and corre-
sponding adjacent normal esophageal tissues. Results showed that
the overall average expression level of miR-203 was lower in tu-
mor tissues than in adjacent normal tissues. In contrast, the overall
average expression levels of Ran and miR-21 were higher in tumor
tissues relative to normal tissues (Fig. 5), indicating that miR-203
expression has an inverse correlation with the expression of Ran
and miR-21 in ESCC when compared to adjacent normal tissues,
which is consistent with our above-mentioned data that ectopic
expression of miR-203 down-regulates miR-21 expression through
targeting Ran.4. Discussion
Deregulation of oncogene and tumor-suppressor gene expres-
sion has been identiﬁed as one of the critical causes of tumorigen-
esis. The recent discovery of miRNAs provides additional new
insights into the molecular mechanism of gene expression control.
It has been reported that miRNA could regulate gene expression by
inducing target mRNA cleavage or translational repression through
binding to its 30-UTR. Aberrant miRNA expression was recently
Fig. 4. The effects of Ran restoration in miR-203-transfected esophageal cancer cells. (A) Representative results of cell migration across membranes without matrigel and the
percentage of cells across membranes was indicated by histogram. Data were shown as means ± SD (n = 3), p < 0.01. (B) Representative results of cell invasion across
membranes with matrigel and the percentage of cells across membranes was indicated by histogram. Data were expressed as means ± SD (n = 3), p < 0.01. (C) The
expression of miR-21 was evaluated by real-time PCR. Data were presented as means ± SD (n = 3), p < 0.01. (D) Xenograft growth in nude mice. 2.0  106 cells were injected
s.c. into one ﬂank of nude mice. Tumor formation was induced by Ran restoration in miR-203-Ec-109 not in lentiviral vector-transfected miR-203-Ec-109 cells. Ec-109 and
MiR-NC + pLCM cells were used as positive control for tumor formation in xenograft mice. (E) Tumor volumes were measured at indicated time-points and shown as average
of duplicate measurements with standard error bars (n = 8 each group). (F) Representative tumor tissues were extracted from mice. (G) Average weight of tumors in nude
mice was calculated and shown as means ± SD, p < 0.05.
F. Zhang et al. / Cancer Letters 342 (2014) 121–129 127found in cancer and recognized as a hallmark of cancer [4,5]. Stud-
ies on miRNA expression proﬁling and their functions in cancer
have indeed provided evidence of the implication of miRNA with
tumor development and progression [4,5]. However, up to date,
only a small proportion of identiﬁed miRNAs have been investi-gated to elucidate their precise biological roles in esophageal
cancer.
Down-regulation of miR-203 has been reported in a number of
different types of cancers including ESCC [24–26]. The aim of cur-
rent work is to elucidate the biological functions of miR-203 in
Fig. 5. Quantitative analysis of the expression of miR-203, Ran and miR-21 in
primary ESCC and corresponding adjacent normal esophageal tissues. Graphical
representation of the results of real-time PCR showing an inverse correlation of
miR-203 expression with its putative target Ran and miR-21 in ESCC tissues and
normal matched control esophageal tissues (n = 12).
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in ESCC cells could signiﬁcantly induce cell apoptosis, suppress cell
proliferation, migration and invasion and inhibit their tumorige-
nicity. The data suggest that miR-203 plays tumor suppressor roles
in esophageal cancer cells. Recently it has been shown that MiR-
203 suppresses the proliferative potential of esophageal cancer
cells and acute lymphoblastic leukemia cells through targeting
DNp63 and ABL1, respectively [19,27] and inhibits the migration
of prostate cancer cells by targeting Lasp1, Ckap2, Wasf1 and
Asap1 [28]. In our present reports, studies on molecular mecha-
nism of miR-203 in tumor suppression revealed that small GTPase
Ran is a direct target gene of miR-203 validated by its remarkable
down-regulation in miR-203-expressed cancer cells and by lucifer-
ase assay. It is consistent with a recent report that Ran up-regula-
tion is correlated with miR-203 down-regulation during the repair
of damaged skin [29].
Ran is a small GTPase of the Ras superfamily and involved in
regulation of multiple important biological processes, especially
in nucleocytoplasmic transport, mitotic spindle assembly and nu-
clear envelope formation. The overexpression of Ran has been ob-
served in diverse tumor types and its up-regulation is correlated
with a poor prognosis of tumor patients, suggesting the impor-
tance of this small GTPase in tumor growth and progression [30–
32]. To speciﬁcally address the implication of Ran in the tumor
suppressive roles of miR-203, wild-type Ran was exogenously ex-
pressed in miR-203-transfected esophageal cancer cells. Our obser-
vations showed that the restoration of Ran partially increased
apoptotic resistance and rescued the suppressive effects of miR-
203 on cell proliferation, migration and invasion. However, our
xenograft experiments showed that Ran restoration could partially
enhance xenograft growth of miR-203-transfected cells in vivo,
suggesting that down-regulation of Ran partially contributed to
the tumor suppressive effects of miR-203.
Signiﬁcant down-regulation of miR-21 was observed in miR-
203-transfected ESCCs. MiR-21 is the only miRNA known to be fre-
quently overexpressed in many types of human malignancy and
actually considered as oncogenic miRNA that acts as oncogene
[22]. Extensive studies showed that its overexpression is involved
in all the known carcinogenic processes such as hyperproliferation,
angiogenesis, invasion and metastasis and signiﬁcantly associated
with the poor prognosis of tumor patients [22,23]. In the present
studies, overexpression of miR-203 led to the down-regulation of
miR-21 expression. We further identiﬁed that Ran was able to reg-
ulate miR-21 expression, and miR-203 could down-regulate miR-
21 expression through repressing Ran. In our experiments, Ran
knockdown by Ran-speciﬁc siRNA reduced the expression of
miR-21 and Ran restoration in miR-203-transfected cells increasedmiR-21 expression and therefore counteracted inhibitory effects of
miR-203 on miR-21 expression. It should be mentioned that it may
be a particular phenomenon observed in Ec-109 cells and be differ-
ent in other cell lines, considering that the pattern of expression of
miRNAs is tissue dependent. Furthermore, an inverse correlation of
miR-203 expression with the expression of Ran and miR-21 was
observed in ESCC tissues when compared to corresponding adja-
cent normal tissues, suggesting that misregulation of miR-203
may be a critical event responsible for the overexpression Ran
and miR-21 in ESCC. This observation is consistent with our data
that miR-203 down-regulates miR-21 expression through sup-
pressing Ran. However, how Ran regulates miR-21 expression re-
mains to be elucidated.
In conclusion, the data presented here suggest that miR-203
plays tumor suppressor roles in esophageal cancer cells and small
GTPase Ran is a direct downstream target of miR-203 which can be
involved in multiple tumor suppressive effects of miR-203. We
established for the ﬁrst time a link between miR-203, small GTPase
Ran and miR-21, which has been identiﬁed as an oncogenic miRNA
ubiquitously overexpressed in diverse types of malignancy. The
identiﬁcation and characterization of the tumor suppressive effects
of miR-203 may provide a novel therapeutic approach for ESCC
treatment.
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